GlassScriptPhysician profile
Willie L Posey, II
NPI 1346219417
$4,681.55
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $247 · 2021: $899 · 2022: $1,240 · 2023: $824 · 2024: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,059.16 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $685.33 | 2021-2024 | Jot Dx, Unify Assura |
| Merck Sharp & Dohme LLC | $498.64 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $385.72 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $349.16 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.93 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $294.86 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $233.78 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.32 | 2020-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $124.20 | 2019-2024 | |
| Pfizer INC. | $121.15 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.82 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $103.83 | 2022-2024 | Rexulti |
| Amgen INC. | $75.65 | 2022 | |
| Lundbeck LLC | $35.24 | 2023-2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $31.50 | 2019 | |
| Smith+Nephew, INC. | $18.15 | 2019 | |
| Currax Pharmaceuticals LLC | $17.31 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.12 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $15.27 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.78 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $13.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2019 | |
| Mylan Specialty L.P. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Posey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.